Commercial COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays
Francisco Belda, Robin Cherenzia, Michael Crowley
doi: https://doi.org/10.1101/2020.09.08.20190256
Francisco Belda
1Research and Development, Bio Supplies Division, Grifols, 08174 Sant Cugat del Vallès (Barcelona), Spain
Robin Cherenzia
2Access Biologicals, Vista, CA 92081, USA
Michael Crowley
2Access Biologicals, Vista, CA 92081, USA
Article usage
Posted September 21, 2020.
Commercial COVID-19 serial seroconversion panel for validation of SARS-CoV-2 antibody assays
Francisco Belda, Robin Cherenzia, Michael Crowley
medRxiv 2020.09.08.20190256; doi: https://doi.org/10.1101/2020.09.08.20190256
Subject Area
Subject Areas
- Addiction Medicine (354)
- Allergy and Immunology (676)
- Anesthesia (182)
- Cardiovascular Medicine (2676)
- Dermatology (227)
- Emergency Medicine (404)
- Epidemiology (12302)
- Forensic Medicine (10)
- Gastroenterology (768)
- Genetic and Genomic Medicine (4148)
- Geriatric Medicine (389)
- Health Economics (684)
- Health Informatics (2688)
- Health Policy (1009)
- Hematology (365)
- HIV/AIDS (859)
- Medical Education (401)
- Medical Ethics (110)
- Nephrology (444)
- Neurology (3930)
- Nursing (212)
- Nutrition (584)
- Oncology (2068)
- Ophthalmology (592)
- Orthopedics (243)
- Otolaryngology (307)
- Pain Medicine (252)
- Palliative Medicine (75)
- Pathology (473)
- Pediatrics (1128)
- Primary Care Research (461)
- Public and Global Health (6572)
- Radiology and Imaging (1418)
- Respiratory Medicine (874)
- Rheumatology (413)
- Sports Medicine (345)
- Surgery (455)
- Toxicology (54)
- Transplantation (189)
- Urology (169)